Norman J Dozier, MD | |
2401 N Treadaway Blvd, Abilene, TX 79601-1953 | |
(325) 676-7700 | |
(325) 676-7991 |
Full Name | Norman J Dozier |
---|---|
Gender | Male |
Speciality | Pain Management |
Experience | 42 Years |
Location | 2401 N Treadaway Blvd, Abilene, Texas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629015003 | NPI | - | NPPES |
123220905 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207LP2900X | Anesthesiology - Pain Medicine | G3306 (Texas) | Secondary |
208VP0014X | Pain Medicine - Interventional Pain Medicine | G3306 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Hendrick Medical Center | Abilene, TX | Hospital |
Entity Name | Norman J Dozier Md Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1720492432 PECOS PAC ID: 4284859810 Enrollment ID: O20140715001378 |
News Archive
For many, the start of a new year means the start of a new workout regimen. It is difficult enough to make the time commitment, but nothing throws off a resolution like an injury.
Staphylococcus aureus (Sa) and methicillin-resistant staph aureus (MRSA) continue to be among the most common pathogens that overwhelm the immune system, causing serious skin, soft tissue and life-threatening blood-borne infections.
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.
Scientists at The Scripps Research Institute have new weapons in the fight against HIV. Their new study, published November 17, 2015 as the cover article of the journal Immunity, describes four prototype antibodies that target a specific weak spot on the virus. Guided by these antibodies, the researchers then mimicked the molecular structure of a protein on HIV when designing their own potential HIV vaccine candidate.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Norman J Dozier, MD Po Box 2587, Abilene, TX 79604-2587 Ph: (325) 676-7700 | Norman J Dozier, MD 2401 N Treadaway Blvd, Abilene, TX 79601-1953 Ph: (325) 676-7700 |
News Archive
For many, the start of a new year means the start of a new workout regimen. It is difficult enough to make the time commitment, but nothing throws off a resolution like an injury.
Staphylococcus aureus (Sa) and methicillin-resistant staph aureus (MRSA) continue to be among the most common pathogens that overwhelm the immune system, causing serious skin, soft tissue and life-threatening blood-borne infections.
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.
Scientists at The Scripps Research Institute have new weapons in the fight against HIV. Their new study, published November 17, 2015 as the cover article of the journal Immunity, describes four prototype antibodies that target a specific weak spot on the virus. Guided by these antibodies, the researchers then mimicked the molecular structure of a protein on HIV when designing their own potential HIV vaccine candidate.
› Verified 8 days ago